- Article title
- Article summary
- Article content
- Multi Field Search
| 2024 | LBL-024 Initiated a single-arm registrational trial of monotherapy in relapsed/refractory advanced EP-NEC |
| LBL-024 Launched the Phase Ib/II trial in combination with chemotherapy in 1L EP-NEC and SCLC | |
| Advancement of our pipeline assets for the treatment of autoimmune diseases, including LBL-051 and LBL-047, into the IND-enabling stage | |
| LBL-024 Received Breakthrough Therapy Designation from the NMPA | |
| LBL-034 Received approval from FDA for Orphan Drug Designation | |
| LBL-024 Received approval from FDA for Orphan Drug Designation |
| 2023 | LBL-034 Received the IND approval from both the NMPA and the FDA, and initiated the Phase I/II trial in China |
| LBL-033 Received the IND approval from both the NMPA and the FDA, and initiated the Phase I/II trial in China |
| 2022 | LBL-024 Launched the Phase I/II trial in China |
| LBL-007 Received IND approval from the NMPA and initiated the Phase Ib/II trial in China | |
| LBL-019 Initiated the Phase I trial in China | |
| Commenced business development operations in the U.S. |
| 2020 | LBL-007 Initiated the Phase Ia in China |
| LBL-007 Obtained IND approval from the FDA |
| 2019 | LBL-007 Obtained IND approval from the NMPA |
| 2015 | Established our in-house research and development team |
